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Abstract
Although the Factor V Leiden (FVL) gene variant is the most prevalent genetic risk factor for
venous thrombosis, only 10% of FVL carriers will experience such an event in their lifetime.
To identify potential FVL modifier genes contributing to this incomplete penetrance, we took
advantage of a perinatal synthetic lethal thrombosis phenotype in mice homozygous for FVL
(F5L/L) and haploinsufficient for tissue factor pathway inhibitor (Tfpi+/-) to perform a sensi-
tized dominant ENU mutagenesis screen. Linkage analysis conducted in the 3 largest pedi-
grees generated from the surviving F5L/L Tfpi+/- mice (‘rescues’) using ENU-induced coding
variants as genetic markers was unsuccessful in identifying major suppressor loci. Whole
exome sequencing was applied to DNA from 107 rescue mice to identify candidate genes
enriched for ENU mutations. A total of 3,481 potentially deleterious candidate ENU variants
were identified in 2,984 genes. After correcting for gene size and multiple testing, Arl6ip5
was identified as the most enriched gene, though not reaching genome-wide significance.
Evaluation of CRISPR/Cas9 induced loss of function in the top 6 genes failed to demon-
strate a clear rescue phenotype. However, a maternally inherited (not ENU-induced) de
novo mutation (Plcb4R335Q) exhibited significant co-segregation with the rescue phenotype
(p = 0.003) in the corresponding pedigree. Thrombosis suppression by heterozygous Plcb4
loss of function was confirmed through analysis of an independent, CRISPR/Cas9-induced
Plcb4 mutation (p = 0.01).
Author summary
Abnormal blood clotting in veins (venous thrombosis) or arteries (arterial thrombosis)
are major health problems, with venous thrombosis affecting approximately 1 in every
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thousand individuals annually in the United States. Susceptibility to venous thrombosis is
governed by both genes and environment, with approximately 60% of the risk attributed
to genetic influences. Though several genetic risk factors are known, >50% of genetic risk
remains unexplained. Approximately 5% of people carry the most common known risk
factor, Factor V Leiden. However, only 10% of these individuals will develop a blood clot
in their lifetime. Mice carrying two copies of the Factor V Leiden mutation together with
a mutation in a second gene called tissue factor pathway inhibitor develop fatal thrombo-
sis shortly after birth. To identify genes that prevent this fatal thrombosis, we studied a
large panel of mice carrying inactivating gene changes randomly distributed throughout
the genome. We identified several genes as potential candidates to alter blood clotting bal-
ance in mice and humans with predisposition to thrombosis, and confirmed this protec-
tive function for DNA changes in one of these genes (Plcb4).
Introduction
Venous thromboembolism (VTE) affects 1:1000 individuals in the US each year and is highly
heritable [1, 2]. A single nucleotide variant (SNV) in the F5 gene, referred to as Factor V Lei-
den (FVL, p.R506G) is present in 5–10% of Europeans, conferring a 2–4 fold increased risk for
VTE [3]. Although ~25% of VTE patients carry the FVL variant [4], only ~10% of individuals
heterozygous for FVL develop thrombosis in their lifetime.
To identify genetic variants that could potentially function as modifiers for FVL-associated
VTE risk, we recently reported a dominant ENU screen [5] in mice sensitized for thrombosis.
Such sensitized screens have been previously successful in identifying modifier genes for various
phenotypes [6–9]. This screen was based on mice homozygous for the FVL mutation (F5L/L)
and haploinsufficient for tissue factor pathway inhibitor (Tfpi+/-). As previously reported, F5L/L
Tfpi+/- mice exhibit normal embryonic development, although nearly all die of widespread, sys-
temic thrombosis in the immediate perinatal period [10]. After ENU mutagenesis, 98 G1 F5L/L
Tfpi+/-progeny survived to weaning (“rescues”) and 16 progeny exhibited successful transmis-
sion of the ENU-induced suppressor mutation. However, subsequent efforts to genetically map
the corresponding suppressor loci were confounded by complex strain-specific differences
introduced by the required genetic outcross [5]. Similar genetic background effects have com-
plicated previous mapping efforts [11] and have been noted to significantly alter other pheno-
types [12, 13]. Additional challenges of this mapping approach include the requirement for
large pedigrees and limited mapping resolution, with candidate intervals typically harboring
tens to hundreds of genes and multiple closely linked mutations.
High throughput sequencing methods have enabled the direct identification of ENU-
induced mutations. Thus, mutation identification in ENU screens is no longer dependent
upon an outcross strategy for gene mapping [14–16]. We now report whole exome sequencing
(WES) of 107 rescue mice (including 50 mice from the previously reported ENU screen [5]).
Assuming loss of gene function as the mechanism of rescue, these WES data were analyzed
gene-by-gene to identify genes enriched with mutations (mutation burden analysis). The
Arl6ip5 gene emerged as the top candidate suppressor locus from this analysis. However, an
independent CRISPR/Cas9-generated Arl5ip5 mutant allele failed to demonstrate highly pene-
trant rescue of the F5L/L Tfpi+/- lethal phenotype. Surprisingly, a maternally inherited (not
ENU-induced) de novo mutation (Plcb4R335Q) exhibited significant co-segregation with the
rescue phenotype (p = 0.003) in an expanded pedigree.
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Results and discussion
Smaller rescue pedigrees on pure C57BL/6J background
In the previously reported ENU screen [5], viable F5L/L Tfpi+/- rescue mice were outcrossed to
the 129S1/SvImJ strain to introduce the genetic diversity required for subsequent mapping
experiments. However, complex strain modifier gene interactions confounded this analysis
and resulted in a large number of “phenocopies” (defined as viable F5L/L Tfpi+/- mice lacking
the original rescue mutation). To eliminate confounding effects of these thrombosis strain
modifiers, we generated an additional 2,834 G1 offspring exclusively maintained on the
C57BL/6J background. The 42 G1 F5L/L Tfpi+/- mice alive at 6 weeks of age were mated to F5L/L
mice to test the heritability of the survival phenotype. Twenty-one of these 42 mice generated
at least one litter and 15 (1 female, 14 males) produced1 offspring with the F5L/L Tfpi+/-
genotype. Fifteen new rescue pedigrees were established from this screen (S1 Table). All pedi-
grees were expanded until all rescues either were infertile or died without producing any prog-
eny with rescue genotype. The frequency, survival, weight, and sex distributions of identified
rescues were consistent with our previous report (S1 Fig). Though many of the pedigrees pre-
viously generated on the mixed 129S1/SvImJ-C57BL/6J background generated >45 rescue
progeny per pedigree (8/16) [5], all pedigrees on the pure C57BL/6J background yielded <36
rescue mice (most generating5 rescues) (S1 Table). Significantly smaller pedigrees in com-
parison to the previous screen (p = 0.010, S2 Fig) are likely explained by a generally positive
effect of the hybrid 129S1/SvImJ-C57BL/6J strain background either directly on rescue fertility
(hybrid vigor) or indirectly by reducing the severity of the F5L/L phenotype. Although a contri-
bution from nongenetic factors cannot be excluded, the C57BL/6J and 129S1/SvImJ strains
have been shown to exhibit significant differences in a number of hemostasis-related parame-
ters, including platelet count and TFPI and tissue factor expression levels [17], with the genetic
variations underlying such strain specific differences likely contributing to the genetic map-
ping complexity noted in the previous report [5].
Linkage analysis using coding ENU variants fails to map suppressor loci
As the rescue pedigrees were maintained on a pure C57BL/6J background, the only genetic
markers that could be used for mapping were ENU-induced variants. WES of one G1 or
G2 member of the three largest pedigrees (1, 6, and 13, S2 Table), identified a total of 86 candi-
date ENU variants that were also validated by Sanger sequencing analysis (S3 Table). Of these
86 candidate genes, 69 were present in the G1 rescue but not its parents (G0), indicating that
they were likely ENU-induced variants. These 69 variants were then further genotyped in all
other rescue progeny in the respective pedigrees. Given the low number of identified genetic
markers (20–26 per pedigree), these three pedigrees were poorly powered (29.6%, 21.7% and
39.4%, respectively) to identify the rescue variants by linkage analysis (S3A–S5A Figs). None
of the 19 ENU variants tested in pedigree 1 (S3B Fig), showed linkage with a LOD-score >1.5
(S3C Fig). Similarly, 26 and 24 variants analyzed in pedigrees 6 and 13, respectively (S4B and
S5B Figs) also failed to demonstrate a LOD-score >1.5 (S4C and S5C Figs). Failure to map the
causal loci in any of these pedigrees was likely due to insufficient marker coverage. However,
in these analyses, we could not exclude the contribution from a non-ENU-induced variant
[18] or an unexpectedly high phenocopy rate. While WES has been successfully applied to
identify causal ENU variants within inbred lines [19] and in mixed background lines [20,
21], whole genome sequencing (WGS) provides much denser and more even coverage of the
entire genome (~3,000 ENU variants/genome expected) and outperforms WES for mapping
[15]. However, a WGS approach requires sequencing multiple pedigree members [16], or
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pooled samples at high coverage [15], resulting in considerably higher expense with current
methods.
WES identifies 6,771 ENU-induced variants in 107 rescues
In order to identify exonic ENU mutations, a total of 107 G1 rescues (57 from the current ENU
screen and an additional 50 rescues with available material from the previous screen [5]), were
subjected to WES (S2 Table). From ~1.5 million initially called variants (34,000 in exonic regions)
6,735 SNVs and 36 insertions-deletions (INDELs) within exonic regions were identified as poten-
tial ENU-induced mutations, using an in-house filtering pipeline (see Materials and methods).
The most common exonic variants were nonsynonymous SNVs (47%), followed by mutations in
3’ and 5’ untranslated regions (31%) and synonymous SNVs (15%). The remaining variants (7%)
were classified as splice site altering, stoploss, stopgain, or INDELs (Fig 1A). T/A -> C/G (47%),
and T/A -> A/T (24%) SNVs were overrepresented, while C/G -> G/C (0.8%) changes were
greatly underrepresented (Fig 1B), consistent with previously reported ENU studies [22, 23].
Since ENU is administered to the G0 father of G1 rescues, only female progeny are expected to
carry induced mutations on the X chromosome, while males inherit their single X chromosome
from the unmutagenized mother. Among the called variants, all chromosomes harbored a similar
number of mutations in both sexes, with the exception of the X chromosome where a>35 fold
increase in SNVs per mouse was observed in females (Fig 1C). The average number of exonic
ENU mutations for G1 rescues was ~65 SNVs per mouse (Fig 1D), consistent with expected ENU
mutation rates [16, 23]. These data suggest that most called variants are likely to be of ENU origin.
Mutation burden analysis identifies potential candidate thrombosis
suppressor genes
WES data for 107 independent rescue mice were jointly analyzed to identify candidate genes
that are enriched for potentially deleterious ENU-induced variants including missense, non-
sense, frameshift, and splice site altering mutations (3,481 out of 6,771 variants in 2,984 genes,
~32.5 potentially deleterious variants per mouse, S4 Table). Similar mutation burden analyses
have been used to identify genes underlying rare diseases caused by de novo loss-of-function
variants in humans [24–27]. In our study, the majority of genes harbored only a single ENU-
induced variant, with 15 SNVs identified in Ttn, the largest gene in the mouse genome (Fig
1E). After adjusting for coding region size and multiple testing (for 2,984 genes), the ENU-
induced mutation burden of potentially deleterious variants was significantly greater than
expected by chance for 3 genes (FDR<0.1, Arl6ip5, Itgb6, C6) and suggestive for 9 additional
genes (FDR<0.25). Sanger sequencing validated 36 of the 37 variants in these 12 candidate
genes (S4 Table). While in this study, stringent correction for multiple testing suggested no sig-
nificant enrichment (Arl6ip5 FDR = 0.68, Fig 2), the potential power of this burden analysis is
highly dependent on the number of possible genes that could result in a viable rescue. If there
were 30 such genes in the genome and every one of the 107 rescue mice carried a mutation in
one of these 30 genes, each gene would be, on average, represented by ~3.5 mutations (107/
30), with>7 genes expected to carry 5 or more mutations, which should have been sufficient
to distinguish from the background mutation rate. However, if 500 genes could rescue the phe-
notype, sequencing close to a thousand mice would be required to achieve sufficient mapping
power. The power could be further compromised by modifier genes with incomplete pene-
trance, imperfect predictions for potentially harmful mutations, and by the previously reported
background survival rate for the rescue mice [10]. Due to the uncertainty of the power of these
analyses, we proceeded to experimentally test the thrombosupressive effects of loss of function
mutations in the genes identified by mutation burden analysis.
Identifying thrombosis modifier genes
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Independent alleles for 6 candidate genes fail to replicate thrombosis
suppression
Independent null alleles were generated with CRISPR/Cas9 for the top candidate genes
(Arl6ip5, C6, Itgb6, Cpn1, Sntg1 and Ces3b; Fig 2) to test for thrombosuppression. From 294
Fig 1. Distribution of ENU-induced mutations in WES data from 107 G1 rescues. A) Overview of mutation types for the 6,771 observed ENU-
induced exonic variants. B) Distribution of missense mutations by nucleotide substitution type. C) Distribution of ENU-variants by chromosome.
D) The average number of exonic SNVs is ~65 for both the current (G1-new) and previous (G1-old) screen [5]. E) Number of genes (x-axis) sorted
by the number of protein-altering ENU-induced mutations observed per gene (y-axis). Most genes (2,567) carry only 1 mutation. In contrast, the
~0.1 megabase coding region of Ttn carries a total of 15 independent ENU variants.
https://doi.org/10.1371/journal.pgen.1007658.g001
Fig 2. Mutation enrichment per gene in WES data from 107 G1 rescues. All genes with potentially deleterious ENU mutations are sorted by
their chromosomal position on the x-axis, with the y-axis indicating the statistical significance (negative log of the p-value) of each gene’s
enrichment based on 106 permutations normalized to coding region size. Each dot represents a gene and the diameter is proportional to the
number of mutations observed. Gray dotted lines represent FDR values of 0.1 and 0.25 (normalized to 2,984 genes carrying mutations). Red
dotted line represents FDR value 0.8 from a more stringent test (normalized to all 20,586 genes in the simulation).
https://doi.org/10.1371/journal.pgen.1007658.g002
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microinjected zygotes with pooled guide RNAs targeting these 6 genes, we obtained 39 prog-
eny. CRISPR/Cas9 genome editing was assessed by Sanger sequencing of the sgRNA target
sites. Approximately 190 independent targeting events were observed across the 6 genes in 36
of the 39 mice including small INDELs, single nucleotide changes, and several large (>30bp)
deletions or inversions. Targeted alleles were either homozygous, heterozygous, or mosaic,
with the number of editing events varying greatly for different sgRNAs (2.5–85%). Two or
more different CRISPR/Cas9-induced alleles for each of the candidate genes (S5 Table) were
bred to isolation but maintained on the F5L background for subsequent test crossing. The
progeny of F5L/L Tfpi+/+ mice crossed with F5L/+ Tfpi+/- mice (one of these parental mice also
carrying the CRISPR/Cas9-induced allele) were monitored for survival of F5L/L Tfpi+/- off-
spring (Table 1, S6 Table).
Over 100 progeny were generated for each of the candidate genes with no obvious rescue
effect. A slight increase in rescues carrying the F5L/L Tfpi+/- Arl6ip5+/- genotype was noted,
although it remained non-significant after surveying 205 offspring (p = 0.21, Table 1).
Our sensitized suppressor screening strategy is highly dependent on the underlying throm-
bosis model. Modifier genes rescuing the F5L/L Tfpi+/- synthetic lethal phenotype are poten-
tially relevant to the common human FVL variant and our previous observations that
mutations in F8 and F3 can rescue F5L/L Tfpi+/- demonstrate the sensitivity of this model to
genetic alterations in coagulation system balance. However, rescue of F5L/L Tfpi+/- lethality by
haploinsufficiency for F3 (the target of TFPI) only exhibits penetrance of ~33% [5], a level of
rescue which current observations cannot exclude for Arl6ip5 and Sntg1. For most of the other
candidate genes, the number of observed F5L/L Tfpi+/- mice did not differ from the expected
background survival rate for this genotype (~2%) [10]. Though higher numbers of rescues
were observed for offspring from the Sntg1 cross, these were equally distributed between mice
with and without the Sntg1 loss-of-function allele.
A Plcb4 mutation co-segregates with the rescue phenotype in 3 G1 siblings
and their rescue offspring
The number of G1 rescues produced from each ENU-treated G0 male is shown in Fig 3A.
Though most of the 182 G0 males yielded few or no G1 rescue offspring, a single G0 produced
6 rescues out of a total of 39 offspring (Fig 3A), including the founder G1 rescue for the largest
pedigree (number 13). This observation suggested a potential shared rescue variant rather
than 6 independent rescue mutations from the same G0 founder. Similarly, another previously
reported ENU screen identified 7 independent ENU pedigrees with an identical phenotype
mapping to the same genetic locus, also hypothesized to result from a single shared mutation
[11]. While rescue siblings could theoretically originate from the same mutagenized spermato-
gonial stem cell and share ~50% of their induced mutations [28], such a common stem cell
Table 1. Testing for rescue effect with CRISPR/Cas9-induced alleles.
Gene Total mice tested No. of rescues w/o allele No. of rescues with allele P-value
Arl6ip5 205 1 5 0.21
Itgb6 154 1 1 1
C6 106 0 0 1
Cpn1 139 0 1 1
Sntg1 223 3 4 1
Ces3b 219 2 1 1
Fisher’s exact test
https://doi.org/10.1371/journal.pgen.1007658.t001
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origin was excluded by exome sequence analysis in the rescue G1 sibs identified here (see
Materials and methods).
Analysis of WES for 3 of the G1 rescues originating from this common G0 founder male
(Fig 3B, S2 Table) identified 3 protein-altering variants (Plcb4R335Q, Pyhin1G157T, and
Fignl2G82S) shared among 2 or more of the 6 G1 rescues (S7 Table). Plcb4R335Q was detected as
a de novo mutation in one of the non-mutagenized G0 females in phase with the Tfpi null allele
(Fig 3B) and was present in 3 out of 6 G1 rescue siblings. Plcb4 is located approximately 50
Fig 3. Plcb4R335Q co-segregates with the rescue phenotype in pedigrees 12 and 13. A) One ENU mating exhibited a significantly higher number of
rescue progeny (n = 6) compared to all ENU matings (p<5x10-5) and compared to ENU matings with1 rescue progeny (p<0.05). B) One female in this
ENU mating carried a de novo SNV (R335Q) in the Plcb4 gene that was inherited in phase with the Tfpi- allele by 3 of the G1 rescues. C) The Plcb4 gene is
loosely linked to the Tfpi locus on chromosome 2, with a predicted recombination rate of 14.1%. No recombination was observed in 40 rescues from
pedigree 12 and 13, while their littermates (n = 149) exhibited close to the expected recombination rate. D) The Plcb4R335Q mutation lies in a highly
conserved region in exon 13 (data from Multiz alignment on UCSC Genome Browser).
https://doi.org/10.1371/journal.pgen.1007658.g003
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megabases upstream of the Tfpi locus on chromosome 2 (predicted recombination between
Plcb4 and Tfpi ~14.1%) (Fig 3C) [29, 30]. While non-rescue littermates exhibited the expected
rate of recombination between the Plcb4R335Q and Tfpi loci (20.2%), all 43 rescue mice (3 G1s
and their 40G2 progeny) were non-recombinant and carried the Plcb4R335Q variant. This co-
segregation between the Plcb4R335Q variant and the rescue phenotype is statistically significant
(p = 0.003; Fig 3C). Plcb4R335Q lies within a highly conserved region of Plcb4 (Fig 3D) and is
predicted to be deleterious by Polyphen-2 [31]. The other identified non-ENU variants
(Pyhin1G157T and Fignl2G82S) did not segregate with the rescue phenotype (S6 Fig).
Although the estimated de novo mutation rate for inbred mice (~5.4 x 10−9 bp/generation)
is 200X lower than our ENU mutation rate, other de novo variants have coincidentally been
identified in ENU screens [32]. Of note, the Plcb4R335Q variant was originally removed from
the candidate list by a filtering step based on the assumption that each ENU-induced mutation
should be unique to a single G1 offspring. Although this algorithm was very efficient for
removing false positive variants in our screen and others [21], our findings illustrate the risk
for potential false negative results that this approach confers.
Independent mutant allele for Plcb4 recapitulates the rescue phenotype
An independent Plcb4 null allele was generated by CRISPR/Cas9. Three distinct INDELs were
identified by Sanger sequencing in the 25 progeny obtained from the CRISPR/Cas9-injected
oocytes. One of these alleles introduced a single nucleotide insertion at amino acid 328, result-
ing in a frameshift in the protein coding sequence and a marked decrease in the steady state
mRNA level from the mutant allele (~2% compared to wildtype), consistent with nonsense-
mediated decay (Plcb4ins1, Fig 4A and 4B). A total of 169 progeny from a F5L/L Plcb4+/ins1 X
F5L/+ Tfpi+/- cross yielded 11 F5L/L Tfpi+/- rescue progeny surviving to weaning (Fig 4C, S8
Table). Ten of these 11 rescues carried the Plcb4ins1 allele, consistent with significant rescue
(p = 0.01, Fig 4C) with reduced penetrance (~40%). Plcb4 encodes phospholipase C, beta 4 and
has been recently associated with auriculocondylar syndrome in humans [33]. No role for
PLCB4 in the regulation of hemostasis has been previously reported, and the underlying mech-
anism for suppression of the lethal F5L/L Tfpi+/- phenotype is unknown.
The above rescue of the F5L/L Tfpi+/- phenotype by an independent Plcb4 mutant allele,
strongly supports the identification of the de novo Plcb4R355Q mutation as the causal suppressor
variant for Pedigree 13. These findings are also most consistent with a loss-of-function mecha-
nism of action for the Plcb4R355Q mutation. The lack of a positive signal from this genomic
region by the linkage analysis described above (S5 Fig) is likely explained by the absence of a
nearby genetically informative ENU variant (the closest, Abca2 is located>50 Mb downstream
from both Tfpi and Plcb4 (S3 Table, S5 Fig)). Of note, 4 of the 107 rescue mice in the WES
mutation burden analysis also carried a Plcb4 mutation consistent with its suppressor function,
though below the level of statistical significance. Nonetheless, these findings highlight the feasi-
bility of our approach, given sufficient power.
In conclusion, we performed a dominant, sensitized ENU mutagenesis screen for modifiers
of thrombosis. Analysis of extended pedigrees identified Plcb4 as a novel thrombosis modifier.
Though mutation burden analysis suggested several other potential modifier loci, including
Arl6ip5, incomplete penetrance and the background phenocopy rate significantly limited the
power to detect additional thrombosis suppressor genes. Future applications of this approach
will likely require significantly larger sample sizes and/or a more stringent sensitized genotype
for screening. Nonetheless, our findings demonstrate the power of a sensitized ENU screen
and mutation burden analysis to identify novel loci contributing to the regulation of hemo-
static balance and candidate modifier genes for thrombosis and bleeding risk in humans.
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Materials and methods
Mice
Mice carrying the murine homolog of the FVL mutation [34] (F5L; also available from Jackson
Laboratories stock #004080) or the TFPI Kunitz domain deletion (Tfpi-) [35] were genotyped
using PCR assays with primers and conditions as previously described [34, 35], and main-
tained on the C57BL/6J background (Jackson Laboratories stock #000664). All animal care
and procedures were performed in accordance with the Principles of Laboratory and Animal
Care established by the National Society for Medical Research. The Institutional Animal Care
and Use Committee at the University of Michigan has approved protocols PRO00005191 and
PRO00007879 used for the current study and conforms to the standards of “The Guide for the
Care and Use of Laboratory Animals” (Revised 2011).
ENU screen
ENU mutagenesis was performed as previously described [5], with all mice on the C57BL/6J
genetic background. Briefly, 189 F5L/L male mice (6–8 weeks old) were administered three
weekly intraperitoneal injections of 90 mg/kg of ENU (N-ethyl-N-nitrosourea, Sigma-
Aldrich). Eight weeks later, 182 surviving males were mated to F5L/+ Tfpi+/- females and their
G1 progeny were genotyped at age 2–3 weeks to identify viable F5L/L Tfpi+/- offspring
Fig 4. An independent CRISPR/Cas9 induced Plcb4 allele validates the rescue phenotype. A) The CRISPR/Cas9-induced Plcb4ins1 allele (insertion of the
nucleotide ‘A’ at amino acid 328) results in a frameshift to the protein coding sequence leading to a premature stop codon. B) Sanger sequencing analysis of gDNA
from a wildtype mouse and both gDNA and cDNA from a Plcb4+/ins1 mouse at the Plcb4 1bp insertion site. C) 169 progeny genotyped from a validation cross of F5L/L
Plcb4+/ins1 mice with F5L/+ Tfpi+/-.
https://doi.org/10.1371/journal.pgen.1007658.g004
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(‘rescues’). F5L/L Tfpi+/- G1 rescues were crossed to F5L/L mice on the C57BL/6J genetic back-
ground (backcrossed >20 generations) and transmission was considered positive with the
presence of one or more rescue progeny. Theoretical mapping power in rescue pedigrees was
estimated by 10,000 simulations using SIMLINK software [36].
Whole exome sequencing
Gender, age, WES details, and other characteristics for 108 rescue mice are provided in S2
Table. Genomic DNA (gDNA) extracted from tail biopsies of 56 G1 offspring from the current
ENU screen and from an additional 50 F5L/L Tfpi+/- mice on the C57BL/6J background from
the previous screen [5] were subjected to WES at the Northwest Genomics Center, University
of Washington. Sequencing libraries were prepared using the Roche NimbleGen exome cap-
ture system. DNA from an additional two rescue offspring was subjected to WES at Beijing
Genomics Institute or Centrillion Genomics Technologies, respectively (S2 Table). These two
libraries were prepared using the Agilent SureSelect capture system. 100 bp paired-end
sequencing was performed for all 108 exome libraries using Illumina HiSeq 2000 or 4000
sequencing instruments. Two WES mice represented rescue pedigree 1: the G1 founder and a
G2 rescue offspring. The latter was used for linkage analysis, but excluded from the burden
analysis (S2 Table).
WES data analysis
Average sequencing coverage, estimated by QualiMap software [37], was 77X, and>96% of
the captured area was covered by at least 6 independent reads (S2 Table). All generated fastq
files have been deposited to the NCBI Sequence Read Archive (Project accession number
#PRJNA397141). A detailed description of variant calling as well as in-house developed scripts
for variant filtration are online as a GitHub repository (github.com/tombergk/FVL_mod). In
short, Burrows-Wheeler Aligner [38] was used to align reads to the Mus Musculus GRCm38
reference genome, Picard [39] to remove duplicates, and GATK [40] to call and filter the vari-
ants. Annovar software [41] was applied to annotate the variants using the Refseq database. All
variants within our mouse cohort present in more than one rescue were declared non-ENU
induced and therefore removed. Unique heterozygous variants with a minimum of 6X cover-
age were considered as potential ENU mutations. Among 107 whole exome sequenced G1
mice, 38 were siblings (13 sib-pairs and 4 trios, S2 Table). 190 heterozygous variants present in
2 or 3 mice (representing sibpairs or trios) out of 107 rescues were examined, with 15 found to
be shared by siblings (S7 Table). Of the 7 sibs/trios sharing an otherwise novel variant, none
shared>10% of their identified variants–inconsistent with the expected 50% for progeny orig-
inating from the same ENU-treated spermatogonial stem cell.
Mutation frequency estimations
All ENU-induced variants predicted to be potentially harmful within protein coding sequences
including missense, nonsense, splice site altering SNVs, and out-of-frame insertions-deletions
(INDELs), were summed for every gene. The number of potentially damaging variants per
gene was compared to a probability distribution of each gene being targeted by chance.
Probability distributions were obtained by running 10 million random permutations using
probabilities adjusted to the length of the protein coding region. A detailed pipeline for the
permutation analysis is available online (github.com/tombergk/FVL_mod). Genes that har-
bored more potentially damaging ENU-induced variants than expected by chance were con-
sidered as candidate modifier genes. FDR statistical correction for multiple testing was applied
as previously described [42].
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Variant validation by Sanger sequencing
All coding variants in pedigrees 1, 6, and 13 as well as all variants in candidate modifier genes
from the burden analysis were assessed using Sanger sequencing. Variants were considered
ENU-induced if identified in the G1 rescue but not its parents. All primers were designed
using Primer3 software [43] and purchased from Integrated DNA Technologies. PCR was per-
formed using GoTaq Green PCR Master Mix (Promega), visualized on 2% agarose gel, and
purified using QIAquick Gel Extraction Kit (Qiagen). Sanger sequencing of purified PCR
products was performed by the University of Michigan Sequencing Core. Outer primers were
used to generate the PCR product which was then sequenced using the internal sequencing
primers. All outer PCR primers (named: gene name+’_OF/OR’) and internal sequencing
primers (named: gene name+’_IF/IR’) are listed in S9 Table.
Guide RNA design and in vitro transcription
Guide RNA target sequences were designed with computational tools [44, 45] (http://www.
broadinstitute.org/rnai/public/analysis-tools/sgrna-design or http://genome-engineering.org)
and top predictions per each candidate gene were selected for functional testing (S10 Table).
Single guide RNAs (sgRNA) for C6, Ces3b, Itgb6, and Sntg1 were in vitro synthesized (MAXI-
script T7 Kit, Thermo Fisher) from double stranded DNA templates by GeneArt gene synthe-
sis service (Thermo Fisher) while the 4 sgRNAs for Arl6ip5 were in vitro synthesized using the
Guide-it sgRNA In Vitro Transcription Kit (Clontech). The sgRNAs were purified prior to
activity testing (MEGAclear Transcription Clean-Up Kit, Thermo Fisher). Both the Wash and
Elution Solutions of the MEGAclear Kit were pre-filtered with 0.02 μm size exclusion mem-
brane filters (Anotop syringe filters, Whatman) to remove particulates from zygote microin-
jection solutions, thus preventing microinjection needle blockages.
in vitro Cas9 DNA cleavage assay
Target DNA for the in vitro cleavage assays was PCR amplified from genomic DNA isolated
from JM8.A3 C57BL/6N mouse embryonic stem (ES) cells [46] with candidate gene specific
primers (S10 Table). In vitro digestion of target DNA was carried out by complexes of syn-
thetic sgRNA and S. pyogenes Cas9 Nuclease (New England BioLabs) according to manufac-
turer’s recommendations. Agarose gel electrophoresis of the reaction products was used to
identify sgRNA molecules that mediated template cleavage by Cas9 protein (S7 Fig). Arl6ip5
was assayed separately, with one out-of-four tested sgRNAs successfully cleaving the PCR
template.
Cell culture DNA cleavage assay
Synthetic sgRNAs that targeted Cpn1 were not identified by the in vitro Cas9 DNA cleavage
assay. As an alternative assay, sgRNA target sequences (Cpn1-g1, Cpn1-g2) were cloned into
plasmid pX330-U6-Chimeric_BB-CBh-hSpCas9 (Addgene.org Plasmid #42230) [47] and co-
electroporated into JM8.A3 ES cells as previously described [48]. Briefly, 15 μg of a Cas9 plas-
mid and 5 μg of a PGK1-puro expression plasmid [49] were co-electroporated into 0.8x107 ES
cells. On days two and three after electroporation media containing 2 μg/ml puromycin was
applied to the cells; then selection free media was applied for four days. Genomic DNA was
purified from surviving ES cells. The Cpn1 region targeted by the sgRNA was PCR amplified
and tested for the presence of indel formation with a T7 endonuclease I assay according to the
manufacturer’s instructions (New England Biolabs).
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Generation of CRISPR/Cas9 gene edited mice
CRISPR/Cas9 gene edited mice were generated in collaboration with the University of Michi-
gan Transgenic Animal Model Core. A premixed solution containing 2.5 ng/μl of each sgRNA
for Arl6ip5, C6, Ces3b, Itgb6, Sntg1, and 5 ng/μl of Cas9 mRNA (GeneArt CRISPR Nuclease
mRNA, Thermo Fisher) was prepared in RNAse free microinjection buffer (10 mM Tris-Hcl,
pH 7.4, 0.25 mM EDTA). The mixture also included 2.5 ng/μl of pX330-U6-Chimeric_BB-
CBh-hSpCas9 plasmid containing guide Cpn1-g1 and a 2.5 ng/μl of pX330-U6-Chimer-
ic_BB-CBh-hSpCas9 plasmid containing guide Cpn1-g2 targeting Cpn1 (S10 Table). The mix-
ture of sgRNAs, Cas9 mRNA, and plasmids was microinjected into the male pronucleus of
fertilized mouse eggs obtained from the mating of stud males carrying the F5L/+ Tfpi+/- geno-
type on the C57BL/6J background with superovulated C57BL/6J female mice. Microinjected
eggs were transferred to pseudopregnant B6DF1 female mice (Jackson Laboratories stock
#100006). DNA extracted from tail biopsies of offspring was genotyped for the presence of
gene editing. The Plcb4 allele was targeted in a separate experiment in collaboration with the
University of Michigan Transgenic Animal Model Core using a pX330-U6-Chimer-
ic_BB-CBh-hSpCas9 plasmid that contained guide Plcb4 (5 ng/μl).
CRISPR allele genotyping
Initially, sgRNA targeted loci were tested using PCR and Sanger sequencing (primer sequences
provided in S10 Table). Small INDELs were deconvoluted from Sanger sequencing reads using
TIDE software [50]. A selection of null alleles from >190 editing events were maintained for
validation (S5 Table). Large (>30 bp) deletions were genotyped using PCR reactions that
resulted in two visibly distinct PCR product sizes for the deletion and wildtype alleles.
Expected product sizes and genotyping primers for each deletion are listed in S5 Table. All
genotyping strategies were initially validated using Sanger sequencing.
Picogreen DNA quantification and qPCR
A qPCR approach was applied to exclude large on-target CRISPR/Cas9-induced deletions. All
DNA samples were quantified using the Quant-iT™ PicoGreen1 dsDNA Assay Kit (Life Tech-
nologies) and analyzed on the Molecular Devices SpectraMax1 M3 multi-mode microplate
reader using SoftMax Pro software and diluted to 5ng/μl. Primer pairs were designed for each
gene using Primer Express 3.0 software (S9 Table) and samples were measured in triplicate
using Power SYBR Green PCR Master Mix (Thermo Fisher Scientific) on a 7900 HT Fast
Real-Time PCR System (Applied Biosystems) with DNA from wildtype C57BL/6J mice used as
a reference. While large CRISPR/Cas9 induced deletions extending the borders of the PCR
primers have been reported [51, 52], qPCR did not detect evidence for a large deletion in any
of the CRISPR targeted genes.
Measurement of relative Plcb4 steady state mRNA levels
The ratio of WT to Plcb4+ins1 mRNA levels was determined as previously described [18]. In
short, a whole brain tissue sample was snap frozen in liquid nitrogen from a Plcb4+/ins1 mouse.
Total RNA was extracted using an RNA extraction kit (Nucleospin RNA from Macherey-
Nagel) and 250 ng of total RNA was converted to complementary DNA (cDNA) using Super-
Script IV One-Step RT-PCR (Invitrogen) following the manufacturer’s instructions. Genotyp-
ing primers spanning the nearest intron (primers Plcb4_cDNA_OF1 and Plcb4_cDNA_OR,
S9 Table) were used to amplify a segment of Plcb4 containing the +1 insertion from the cDNA
samples. PCR products were extracted from agarose gels using a QIAquick Gel Purification
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Kit (Qiagen) and submitted for Sanger sequencing (primer Plcb4_cDNA_OF2, S9 Table). The
differential allelic expression was estimated from the ratio between the wildtype and Plcb4ins1
sequence peak areas in the cDNA sample compared to gDNA using Phred software [53]. This
ratio was calculated for 10 consecutive positions within the PCR product where the wildtype
and Plcb4ins1 alleles contain a different nucleotide.
Statistical analysis
Kaplan-Meier survival curves and a log-rank test to estimate significant differences in mouse
survival were performed using the ‘survival’ package in R [54]. A paired two-tailed Student’s
t-test was applied to estimate differences in weights between rescue mice and their littermates.
Fisher’s exact tests were applied to estimate deviations from expected proportions in mouse
crosses. Mendelian segregation for CRISPR/Cas9-induced alleles among non-rescue litter-
mates was assessed in a subset of mice by Sanger sequencing and then assumed for the rest of
the littermates in the Fisher’s exact tests. Benjamini and Hochberg FDR for ENU burden anal-
ysis, Student’s t-tests, and Fisher’s exact tests were all performed using the ‘stats’ package in R
software [55]. Linkage analysis was performed on the Mendel platform version 14.0 [56] and
LOD scores3.3 were considered genome-wide significant [57].
Supporting information
S1 Fig. A sensitized ENU suppressor screen for thrombosis modifiers. A) The ENU
screen strategy is depicted here, along with the total numbers of G1 offspring observed by
genotype. B) Survival curves for G1 rescue mice. Approximately 50% of the rescue mice died
by 6 weeks of age, with no significant survival difference observed between females and males
(p = 0.077), though females were underrepresented compared to males during the initial geno-
typing (28 females compared to 48 males, p = 0.022). C-D) Weight at genotyping (at 14–21
days) was on average 25–30% smaller for G1 rescues than their littermates (p = 7x10-13). E)
Survival of rescue mice beyond G1 (G2) is also reduced, with worse outcome in females
(p = 0.002). Across all pedigrees, mice beyond G1 (G2) continued to exhibit reduced survival
with more pronounced underrepresentation of females (p = 0.002), and F) an average ~22%
lower body weight compared to littermates (mean defined as 100%) at the time of genotyping
(p = 2x10-16).
(PDF)
S2 Fig. Size distribution of ENU pedigrees. The ENU rescue pedigrees from the previous
screen (n = 16, [5]) are significantly larger than the ENU rescue pedigrees observed in the cur-
rent screen (p = 0.010, n = 15, S1 Table).
(PDF)
S3 Fig. Genetic mapping of ENU-induced variants in pedigree 1. A) Overview of pedigree 1
(only rescue mice displayed). B) All coding ENU-induced mutations identified by WES were
genotyped in all rescues from the pedigree by Sanger sequencing. Blue boxes indicate presence
and red boxes indicate absence of the mutation. P1-P3 refers to 3 parental genotypes (G0 male
and 2 untreated females). C) Linkage analysis using the ENU-induced variants from (B) as
genetic markers.
(PDF)
S4 Fig. Genetic mapping of ENU-induced variants in pedigree 6. A) Overview of pedigree 6
(only rescue mice displayed). B) All coding ENU-induced mutations identified by WES were
genotyped in most rescues from the pedigree by Sanger sequencing. Blue boxes indicate pres-
ence and red boxes indicate absence of the mutation. P1-P3 refers to 3 parental genotypes (G0
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male and 2 untreated females). C) Linkage analysis using the ENU-induced variants from (B)
as genetic markers.
(PDF)
S5 Fig. Genetic mapping of ENU variants in pedigree 13. A) Overview of pedigree 13 (only
rescue mice displayed). B) All coding ENU-induced mutations identified by WES were geno-
typed in all rescues from the pedigree if present in key mice 3 and 5 by Sanger sequencing.
Blue boxes indicate presence and red boxes indicate absence of the mutation. P1-P3 refers to 3
parental genotypes (G0 male and 2 untreated females). C) Linkage analysis using the ENU-
induced variants from (B) as genetic markers.
(PDF)
S6 Fig. Segregation analysis for Pyhin1 and Fignl2 in pedigree 13. Segregation analysis in
pedigree 13 for A) Pyhin1 and B) Fignl2 variants. Blue boxes indicate presence and red boxes
indicate absence of the mutation. White boxes indicate untested mice, while light red boxes
indicate untested mice with assumed absence of the mutation.
(PDF)
S7 Fig. In vitro cleavage assay for sgRNAs. A) sgRNA+Cas9 targeting created double strand
breaks in DNA templates obtained from genomic DNA by PCR. Expected sizes after sgRNA
+Cas9 endonuclease activity: 430bp/240bp (Ces3b), 334bp/273bp (Sntg1), 530bp/275bp
(Itgb6), and 383bp/296bp (C6). B) sgRNA+Cas9 complexes targeting Cpn1 using two different
guides (g1, g2) failed to generate detectable double strand breaks. Positive control (P.C.) was
added to ensure Cas9 protein activity, with expected sizes after cleavage (390bp/140bp) indi-
cated by white stars.
(PDF)
S1 Table. Overview of successfully progeny tested rescues.
(XLSX)
S2 Table. Rescue mice subjected to WES.
(XLSX)
S3 Table. Variants identified for pedigrees 1, 6, and 13.
(XLSX)
S4 Table. ENU-induced coding variants in WES data.
(XLSX)
S5 Table. CRISPR/Cas9 induced alleles.
(XLSX)
S6 Table. Validation crosses with CRISPR/Cas9 induced alleles.
(XLSX)
S7 Table. Shared variants between 2–3 mice in WES data.
(XLSX)
S8 Table. Plcb4ins1 validation cross.
(XLSX)
S9 Table. Primer sequences.
(XLSX)
S10 Table. Sequences and genotyping data for gRNAs.
(XLSX)
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